The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients

被引：13
|
作者：
Amin, Arwa M. [1 ]
Chin, Lim Sheau [1 ]
Noor, Dzul Azri Mohamed [1 ]
Mostafa, Hamza [1 ]
Kader, Muhamad Ali S. K. Abdul [1 ,2 ]
Hay, Yuen Kah [1 ]
Ibrahim, Baharudin [1 ]
机构：
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia
[2] Hosp Pulau Pinang, Cardiol Dept, George Town, Penang, Malaysia
来源：
THROMBOSIS RESEARCH | 2017年 / 158卷
关键词：
CYP2C19; Clopidogrel; Dual antiplatelet therapy (DAPT); Coronary artery disease patients; VerifyNow; High on treatment platelets reactivity; CLINICAL-OUTCOMES; THERAPY; IMPACT; RISK;
D O I：
10.1016/j.thromres.2017.07.032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：22 / 24
页数：3
相关论文
共 50 条
  • [31] CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have No Effect on the Anti-Platelet Action of Clopidogrel
    El-Halabi, Mustapha
    Malli, Ahmad
    Mansour, Nabil
    Ghaith, Ola
    Saab, Rayan
    Mahfouz, Rami
    Alam, Samir
    Zgheib, Nathalie
    Sharara, Ala
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S51 - S51
  • [32] The Influence of Genetic Polymorphism of Cyp2c19 Isoenzyme on the Pharmacokinetics of Clopidogrel and Its Metabolites in Patients With Cardiovascular Diseases
    Karazniewicz-Lada, Marta
    Danielak, Dorota
    Rubis, Blazej
    Burchardt, Pawel
    Oszkinis, Grzegorz
    Glowka, Franciszek
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (08): : 874 - 880
  • [33] Consistent and potent platelet inhibition of prasugrel irrespective of CYP2C19 polymorphism in Japanese patients with coronary artery disease
    Nishikawa, M.
    Isshiki, T.
    Ogawa, H.
    Kimura, T.
    Yokoi, H.
    Nanto, S.
    Takayama, M.
    Kitagawa, K.
    Miyazaki, S.
    Origasa, H.
    Sase, K.
    Umemura, K.
    Ikeda, Y.
    Yamaguchi, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 336 - 336
  • [34] Genetic polymorphisms of CYP2C19 and effect of CYP2C19☆2 allele on clopidogrel P2Y12 inhibition in healthy Malaysian volunteers
    Sani, Y. N.
    Lim, S. C.
    Lim, L. H.
    Edwin, N. E. Y.
    Khan, N. Abdul Karim
    Goh, T. H.
    Serebruany, V. L.
    Yuen, K. H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 874 - 874
  • [35] Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Varenhorst, Christoph
    James, Stefan
    Erlinge, David
    Brandt, John T.
    Braun, Oscar O.
    Man, Michael
    Siegbahn, Agneta
    Walker, Joseph
    Wallentin, Lars
    Winters, Kenneth J.
    Close, Sandra L.
    EUROPEAN HEART JOURNAL, 2009, 30 (14) : 1744 - 1752
  • [36] The effect of CYP2C19 and CYP2C9 polymorphism on the pharmacodynamics of clopidogrel
    Jiang, Juanjuan
    Tian, Lei
    Han, Lulu
    Yan, Yan
    Huang, Yiling
    Liu, Hong
    Xie, Shuang
    Li, Yishi
    CARDIOLOGY, 2011, 120 : 30 - 31
  • [37] Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
    Siasos, Gerasimos
    Zaromitidou, Marina
    Oikonomou, Evangelos
    Mourouzis, Konstantinos
    Tsalamandris, Sotiris
    Kioufis, Stamatios
    Kokkou, Eleni
    Vavuranakis, Manolis
    Zografos, Theodoros
    Antonopoulos, Alexis
    Dimitropoulos, Stathis
    Stefanadis, Christodoulos
    Papavassiliou, Athanasios G.
    Tousoulis, Dimitris
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (34) : 5041 - 5046
  • [38] Haplotype analyses of CYP2C19*2 and CYP2C19*17 genetic polymorphisms in clopidogrel non-responsiveness after percutaneous coronary intervention with stent implantation
    Saydam, F.
    Degirmenci, I.
    Birdane, A.
    Ozdemir, M.
    Ozbayer, C.
    Ata, N.
    Gunes, H. V.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 683 - 683
  • [39] Prevalence and types of genetic polymorphisms of CYP2C19 and their effects on platelet aggregation inhibition by clopidogrel
    Aga, Q. A. A.
    Hasan, M. K.
    Nassir, K. F.
    Aga, L. A. A.
    Al-Jaidi, B. A.
    Aldhoun, M.
    Morsy, M. A.
    Nair, A. B.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (21) : 11286 - 11294
  • [40] Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics
    Djebli, Nassim
    Fabre, David
    Boulenc, Xavier
    Fabre, Gerard
    Sultan, Eric
    Hurbin, Fabrice
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (04) : 510 - 522
12345